Victory Capital Management Inc. cut its stake in Diplomat Pharmacy, Inc. (NYSE:DPLO) by 38.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 625,560 shares of the company’s stock after selling 391,650 shares during the quarter. Victory Capital Management Inc. owned about 0.92% of Diplomat Pharmacy worth $12,955,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after purchasing an additional 3,056 shares during the period. State of Alaska Department of Revenue raised its position in Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after purchasing an additional 3,833 shares during the period. PNC Financial Services Group Inc. raised its position in Diplomat Pharmacy by 46.7% in the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares during the period. Municipal Employees Retirement System of Michigan raised its position in Diplomat Pharmacy by 4.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after purchasing an additional 480 shares during the period. Finally, Janney Montgomery Scott LLC raised its position in Diplomat Pharmacy by 11.9% in the second quarter. Janney Montgomery Scott LLC now owns 11,193 shares of the company’s stock valued at $166,000 after purchasing an additional 1,193 shares during the period. 66.51% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Victory Capital Management Inc. Cuts Holdings in Diplomat Pharmacy, Inc. (DPLO)” was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/14/victory-capital-management-inc-cuts-holdings-in-diplomat-pharmacy-inc-dplo.html.
A number of analysts have recently issued reports on the company. Robert W. Baird reaffirmed a “buy” rating and set a $20.00 target price on shares of Diplomat Pharmacy in a research report on Sunday, September 17th. BidaskClub lowered Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Needham & Company LLC assumed coverage on Diplomat Pharmacy in a research report on Friday, July 21st. They set a “buy” rating and a $19.75 target price on the stock. Mizuho set a $16.00 target price on Diplomat Pharmacy and gave the stock a “hold” rating in a research report on Tuesday, October 24th. Finally, Zacks Investment Research lowered Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Diplomat Pharmacy presently has a consensus rating of “Hold” and an average price target of $20.06.
Diplomat Pharmacy, Inc. (NYSE DPLO) opened at $19.80 on Tuesday. The company has a market capitalization of $1,354.03, a PE ratio of 25.53, a P/E/G ratio of 3.54 and a beta of 0.74. Diplomat Pharmacy, Inc. has a 52 week low of $12.25 and a 52 week high of $21.99. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period last year, the firm earned $0.21 earnings per share. analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current fiscal year.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.